
Tuesday, November 17, 2026
Robert LeBoyer, Senior Vice President, Equity Research Analyst, Biotechnology, Noble Capital Markets, Inc.
Refer to the full report for the price target, fundamental analysis, and rating.
3Q26 Included Progress On OLC. Unicycive reported a 3Q26 loss of $7.0 million or $(0.25) per share, consistent with our expected loss of $3.8 million. During the quarter, Unicycive completed the NDA resubmission for OLC (oxylanthanum carbonate). The new PDUFA date for an answer to the application is March 25, 2027, and launch preparations continue. Cash on September 30, 2026, was $59.0 million.
Contract Manufacturing Partner Has Been Inspected. Unicycive reported that the FDA recently inspected its original manufacturing vendor. The company has not been told the outcome, but compliance with the FDA’s required Good Manufacturing Practices (GMP) could shorten the review period, allowing an earlier launch and higher first-year sales.
Get the Full Report
Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.
This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).
*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision.
